Related Experiment Videos
Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas
J C Cigudosa1, N Z Parsa, D C Louie
1Laboratory of Cancer Genetics, Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Genes, Chromosomes & Cancer
|May 25, 1999
Summary
Cytogenetic analysis of diffuse large B-cell lymphoma (DLBCL) revealed frequent chromosomal abnormalities, with specific breakpoints at 14q32, 18q21, and 1q21 being particularly common. These findings highlight key genetic alterations in DLBCL, aiding future research into its development and treatment.
Area of Science:
- Hematology
- Oncology
- Cytogenetics
Background:
- Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
- Understanding the cytogenetic landscape of DLBCL is crucial for elucidating its pathogenesis and identifying potential therapeutic targets.
Purpose of the Study:
- To comprehensively characterize the cytogenetic abnormalities in a cohort of DLBCL biopsy specimens.
- To identify recurring chromosomal breakpoints and deletions associated with DLBCL development.
Main Methods:
- Cytogenetic analysis (karyotyping) was performed on 363 DLBCL biopsy specimens.
- Analysis focused on identifying clonal chromosomal abnormalities, including translocations and deletions.
- Breakpoints were mapped to specific chromosomal bands.
Main Results:
- Of 248 successfully karyotyped samples, 87% exhibited clonal chromosomal abnormalities.
- Recurring breakpoints were identified at 10 sites, notably 14q32, 18q21, and 1q21.
- Frequent translocations involved 14q32 (51%), with specific types like t(14;18) and t(8;14) noted.
- Eleven common deletion sites were identified, suggesting potential tumor suppressor gene loss.
Conclusions:
- This study provides a detailed cytogenetic profile of DLBCL.
- Recurring chromosomal alterations, particularly at 14q32, 18q21, and 1q21, are characteristic of DLBCL.
- The identified cytogenetic changes lay the groundwork for investigating molecular mechanisms and clinical relevance in DLBCL.